“Netherton Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Netherton Syndrome Market.
The Netherton Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Netherton Syndrome Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Netherton Syndrome treatment therapies with a considerable amount of success over the years.
-
Netherton Syndrome companies working in the treatment market are Quoin Pharmaceutical, Boehringer Ingelheim, LifeMax Laboratories, Novartis, Daiichi Sankyo, Quoin Pharmaceuticals, Children’s Hospital of Philadelphia, and others, are developing therapies for the Netherton Syndrome treatment
-
Emerging Netherton Syndrome therapies in the different phases of clinical trials are- QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, and others are expected to have a significant impact on the Netherton Syndrome market in the coming years.
-
In June 2024, Azitra is advancing ATR-12 as its primary candidate for treating Netherton Syndrome (NS), a rare condition. ATR-04, its second candidate, aims at managing epidermal growth factor receptor inhibitor (EGFRi)-associated rash, while ATR-01 targets ichthyosis vulgaris. These treatments are all formulated for topical use. Preclinical studies have demonstrated the safety and effectiveness of ATR-12, potentially serving as a disease-modifying therapy by colonizing the skin and restoring deficient proteins. Azitra has received Investigational New Drug (IND) clearance for ATR-12 and has initiated a Phase I clinical trial.
-
In May 2024, BioCryst Pharmaceuticals plans to progress BCX17725, a KLK-5 inhibitor intended for Netherton syndrome treatment, into clinical trials by late 2024.
-
In March 2024, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company specializing in rare and orphan diseases, received clearance from the U.S. Food and Drug Administration (FDA) to enroll adolescents aged 14 years and older in its two current clinical trials for QRX003. This medication is being developed as a potential treatment for Netherton Syndrome (NS), and both trials are operating under Quoin’s active Investigational New Drug Application (IND) for QRX003.
Netherton Syndrome Overview
Netherton syndrome is a rare genetic disorder characterized by a triad of clinical features: ichthyosis (a skin condition that leads to dry, scaly skin), trichorrhexis invaginata (bamboo hair, where the hair shafts are fragile and can break easily), and atopic diathesis (a tendency to develop allergies such as asthma, hay fever, or eczema).
Get a Free Sample PDF Report to know more about Netherton Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/netherton-syndrome-pipeline-insight
Emerging Netherton Syndrome Drugs Under Different Phases of Clinical Development Include:
-
QRX003: Quoin Pharmaceutical
-
SPEVIGO (spesolimab/BI 655130): Boehringer Ingelheim
-
LM-030 (BPR277): LifeMax Laboratories/Novartis
-
DS-2325a: Daiichi Sankyo
-
Pimecrolimus: Children’s Hospital of Philadelphia
Netherton Syndrome Route of Administration
Netherton Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Netherton Syndrome Molecule Type
Netherton Syndrome Products have been categorized under various Molecule types, such as
-
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Netherton Syndrome Pipeline Therapeutics Assessment
-
Netherton Syndrome Assessment by Product Type
-
Netherton Syndrome By Stage and Product Type
-
Netherton Syndrome Assessment by Route of Administration
-
Netherton Syndrome By Stage and Route of Administration
-
Netherton Syndrome Assessment by Molecule Type
-
Netherton Syndrome by Stage and Molecule Type
DelveInsight’s Netherton Syndrome Report covers around 5+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Netherton Syndrome product details are provided in the report. Download the Netherton Syndrome pipeline report to learn more about the emerging Netherton Syndrome therapies
Some of the key companies in the Netherton Syndrome Therapeutics Market include:
Key companies developing therapies for Netherton Syndrome are – Sixera Pharma Ab, Dermelix Biotherapeutics, Matrisys Bioscience, Lifemax Laboratories, Azitra Inc, Quoin Pharmaceuticals,, Krystal Biotech, and others,
Netherton Syndrome Pipeline Analysis:
The Netherton Syndrome pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Netherton Syndrome with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Netherton Syndrome Treatment.
-
Netherton Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Netherton Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Netherton Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Netherton Syndrome drugs and therapies
Netherton Syndrome Pipeline Market Strengths
-
The pathogenesis basis of Netherton syndrome is well understood, with a definite link to mutations in the SPINK5 gene that have led to the discovery of potential pathways like IL-7 and KLK inhibition.
-
Advocacy and support groups for Netherton syndrome are spreading awareness and providing a platform for medical experts, researchers, and patients to collaborate.
Netherton Syndrome Pipeline Market Opportunities
-
IV immunoglobulin therapy in pediatrics has presented effective results, and continuous research in this area can lead to the development of disease-modifying therapies
-
Studies have demonstrated the potential of gene therapy ingenodermatosis. Thus, developing therapies like replacement therapy and gene therapy can cure Netherton Syndrome.
Scope of Netherton Syndrome Pipeline Drug Insight
-
Coverage: Global
-
Key Netherton Syndrome Companies: Quoin Pharmaceutical, Boehringer Ingelheim, LifeMax Laboratories, Novartis, Daiichi Sankyo, Quoin Pharmaceuticals, Children’s Hospital of Philadelphia, and others
-
Key Netherton Syndrome Therapies: QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, and others
-
Netherton Syndrome Therapeutic Assessment: Netherton Syndrome current marketed and Netherton Syndrome emerging therapies
-
Netherton Syndrome Market Dynamics: Netherton Syndrome market drivers and Netherton Syndrome market barriers
Request for Sample PDF Report for Netherton Syndrome Pipeline Assessment and clinical trials
Table of Contents
1. Netherton Syndrome Report Introduction
2. Netherton Syndrome Executive Summary
3. Netherton Syndrome Overview
4. Netherton Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Netherton Syndrome Pipeline Therapeutics
6. Netherton Syndrome Late Stage Products (Phase II/III)
7. Netherton Syndrome Mid Stage Products (Phase II)
8. Netherton Syndrome Early Stage Products (Phase I)
9. Netherton Syndrome Preclinical Stage Products
10. Netherton Syndrome Therapeutics Assessment
11. Netherton Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Netherton Syndrome Key Companies
14. Netherton Syndrome Key Products
15. Netherton Syndrome Unmet Needs
16 . Netherton Syndrome Market Drivers and Barriers
17. Netherton Syndrome Future Perspectives and Conclusion
18. Netherton Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services